Use of zwitterionic polysaccharides for the specific...

Details Use of zwitterionic polysaccharides for the specific... Use of zwitterionic polysaccharides for the specific...

2011-08-30

2011-08-30

Lewis, Patrick (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S123100

Reexamination Certificate

active

08008276

ABSTRACT:
The invention relates to three-dimensional molecular structure determination of polymers, three-dimensional computer molecular modeling, rational drug design, and immunomodulatory polymers. In particular the invention is directed to immunomodulatory polymers, as well as to methods for designing, selecting, and screening therapeutic agents having immunomodulatory activity.

REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 4619995 (1986-10-01), Hayes
patent: 4782067 (1988-11-01), Blythin et al.
patent: 4819617 (1989-04-01), Goldberg et al.
patent: 4835252 (1989-05-01), Musso et al.
patent: 4886787 (1989-12-01), de Belder et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 5126141 (1992-06-01), Henry
patent: 5130417 (1992-07-01), Stanley et al.
patent: 5140016 (1992-08-01), Goldberg et al.
patent: 5158939 (1992-10-01), Takayama et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5215896 (1993-06-01), Keck et al.
patent: 5331573 (1994-07-01), Balaji et al.
patent: 5514581 (1996-05-01), Ferrari et al.
patent: 5532221 (1996-07-01), Huang et al.
patent: 5576002 (1996-11-01), Jennings et al.
patent: 5605938 (1997-02-01), Roufa et al.
patent: 5679654 (1997-10-01), Tzianabos et al.
patent: 5679658 (1997-10-01), Elson
patent: 5700787 (1997-12-01), Tzianabos et al.
patent: 5700906 (1997-12-01), Arnot et al.
patent: 5705178 (1998-01-01), Roufa et al.
patent: 5760200 (1998-06-01), Miller et al.
patent: 5888741 (1999-03-01), Hendry
patent: 5993825 (1999-11-01), Jennings et al.
patent: 6110672 (2000-08-01), Mandel et al.
patent: 6150459 (2000-11-01), Mayes et al.
patent: 6294518 (2001-09-01), Potter et al.
patent: 6447765 (2002-09-01), Horwitz
patent: 6995237 (2006-02-01), Zimmerman
patent: 7026285 (2006-04-01), Tzianabos et al.
patent: 7083777 (2006-08-01), Tzianabos et al.
patent: 7163683 (2007-01-01), Barstad et al.
patent: 7166455 (2007-01-01), Comstock et al.
patent: 7629330 (2009-12-01), Wang et al.
patent: 7678558 (2010-03-01), Comstock et al.
patent: 7803602 (2010-09-01), Comstock et al.
patent: 2001/0001788 (2001-05-01), Satoh et al.
patent: 2002/0090357 (2002-07-01), Barrat et al.
patent: 2003/0219413 (2003-11-01), Comstock et al.
patent: 2004/0092433 (2004-05-01), Wang et al.
patent: 2004/0219160 (2004-11-01), Tzianabos et al.
patent: 2005/0119164 (2005-06-01), Taylor et al.
patent: 2006/0153832 (2006-07-01), Tzianabos et al.
patent: 2007/0020730 (2007-01-01), Comstock et al.
patent: 2008/0057565 (2008-03-01), Comstock et al.
patent: 2009/0124573 (2009-05-01), Mazmanian et al.
patent: 2009/0317427 (2009-12-01), Kasper et al.
patent: 2010/0311686 (2010-12-01), Kasper et al.
patent: 2011/0059125 (2011-03-01), Tzianabos et al.
patent: 3704389 (1988-08-01), None
patent: 1358885 (2003-11-01), None
patent: 1459757 (2004-09-01), None
patent: 2286193 (1995-08-01), None
patent: 56128721 (1981-10-01), None
patent: WO 95/31990 (1995-11-01), None
patent: WO 96/07427 (1996-03-01), None
patent: WO 96/32119 (1996-10-01), None
patent: WO 96/35433 (1996-11-01), None
patent: WO 00/01733 (2000-01-01), None
patent: WO 00/59515 (2000-10-01), None
patent: WO 02/45708 (2002-06-01), None
patent: WO 03/075953 (2003-09-01), None
patent: WO 03/077863 (2003-09-01), None
patent: WO 2004/089407 (2004-10-01), None
patent: WO 2007/092451 (2007-08-01), None
patent: WO 2009/062132 (2009-05-01), None
GenBank Accession No. AJ277832; Hutloff Jan. 19, 2001.
GenBank Accession No. CAC06612; Hutloff Jan. 19, 2001.
GenBank Accession No. NM—012092; Dec. 20, 2003.
GenBank Accession No. NP—036224 Dec. 20, 2003.
No Author Listed, Lupus study. Meet A Lupus Researcher. www.lupusstudy.org/updates.php.2005;1-2.
No Author Listed, Polyethylene Glycols (PEGs). Accessed Mar. 7, 2005. 1 page. http://www.mindfully.org/Plastic/Polymers/Polyethylene-Glycols-PEGs.htm.
No Author Listed, The Merck Index . Eleventh Edition 1989:734-735.
Aharoni et al., Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. Nov. 2, 1998;91(1-2):135-46.
Aharoni et al., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. Sep. 30, 1997;94(20):10821-6.
Aharoni et al., Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. Immunol Lett. Jul. 1997;58(2):79-87.
Akbari et al., Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med. Sep. 2002;8(9):1024-32. Epub Jul. 29, 2002.
Arnon et al., New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol. Apr. 1996;243(4 Suppl 1):S8-13. Review.
Barrat et al., In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. Mar. 4, 2002;195(5):603-16.
Basu et al., Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem. Jul.-Aug. 1997;8(4):481-8.
Batta et al., Conformational stabilization of the altruronic acid residue in the O-specific polysaccharide ofShigella sonnei/Plesiomonas shigelloides. Carbohydr Res. Dec. 1997;305(1):93-9.
Baumann et al., Structural elucidation of two capsular polysaccharides from one strain ofBacteroides fragilisusing high-resolution NMR spectroscopy. Biochemistry. Apr. 28, 1992;31(16):4081-9.
Bazan et al., Unraveling the structure of IL-2. Science. Jul. 17, 1992;257(5068):410-3.
Boes et al., Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. Feb. 1, 2000;97(3):1184-9.
Brubaker et al., Mitogenic activity of purified capsular polysaccharide A fromBacteroides fragilis: differential stimulatory effect on mouse and rat lymphocytes in vitro. J Immunol. Feb. 15, 1999;162(4):2235-42.
Büdinger et al., Immunologic mechanisms in hypersensitivity reactions to metal ions: an overview. Allergy. Feb. 2000;55(2):108-15. Review.
Cobb et al., Zwitterionic capsular polysaccharides: the new MHCII-dependent antigens. Cell Microbiol. Oct. 2005;7(10):1398-403. Review.
Comstock et al., Interstrain variation of the polysaccharide B biosynthesis locus ofBacteroides fragilis: characterization of the region from strain 638R. J Bacteriol. Oct. 1999;181(19):6192-6.
Coyne et al.,Bacteroides fragilisNCTC9343 produces at least three distinct capsular polysaccharides: cloning, characterization, and reassignment of polysaccharide B and C biosynthesis loci. Infect Immun. Nov. 2000;68(11):6176-81.
Crabb et al., T cell regulation ofBacteroides fragilis-induced intraabdominal abscesses. Rev Infect Dis. Jan.-Feb. 1990;12 Suppl 2:S178-84. Review.
Craig, Autologous hematopoietic stem cell transplantation for Crohn's disease. Autoimmun Rev. Aug. 2002;1(4):244-9. Review.
Dahiyat et al., De novo protein design: fully automated sequence selection. Science. Oct. 3, 1997;278(5335):82-7.
Di Fabio et al., Structure of the capsular polysaccharide antigen of type IV group BStreptococcus. Can J Cancer. 1989;67:877-882.
Finberg et al., Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J Immunol. Sep. 15, 1992;149(6):2055-60.
Fournier et al., Isolation of type 5 capsular polysaccharide fromStaphylococcus aureus. Ann Inst Pasteur Microbiol. Sep.-Oct. 1987;138(5):561-7.
Fridkis-Hareli et al., Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol. Apr. 15, 1999;162(8):4697-704.
Fridkis-Hareli et al., Binding of random copolymers of three amino acids to class II MHC molecules. Int Immunol. May 1999;11(5):635-41.
Fridkis-Hareli et al., Direct binding of myelin basic protein and synthetic copolymer I to class II major histocom

Affiliated with

Also associated with

Rating

Use of zwitterionic polysaccharides for the specific... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of zwitterionic polysaccharides for the specific..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of zwitterionic polysaccharides for the specific... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2789720